Programmed Cell Death 1 + Selected Cell Therapy With Durvalumab (MEDI4736) and Tremelimumab in Metastatic Melanoma
Clinical trial NCT04223648 · WITHDRAWN
Trial details
- NCT number
- NCT04223648
- Sponsor
- Yale University
- Status
- WITHDRAWN
- Phase
- Early Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2020-08-15
- Primary completion
- 2022-02-01
- Enrollment
- 0
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.